Last reviewed · How we verify
Onabotulinumtoxin A
Onabotulinumtoxin A is a Botulinum toxin Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: Botox, Botulinum toxin, Dysport, BOTOX.
Onabotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Onabotulinumtoxin A is used to treat various conditions, including cutaneous leiomyomas, hereditary leiomyomatosis and renal cell cancer, interstitial cystitis, and cerebral palsy. It is administered through injections of botulinum toxin type A, which is a neurotoxin that blocks nerve signals.
At a glance
| Generic name | Onabotulinumtoxin A |
|---|---|
| Also known as | Botox, Botulinum toxin, Dysport, BOTOX, Botox ®, "Allergan" |
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Urology |
| Phase | FDA-approved |
Mechanism of action
The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, leading to localized muscle weakness or paralysis that typically lasts 3-4 months. The effect is temporary because the body gradually regenerates new nerve terminals.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Severe primary axillary hyperhidrosis
- Urinary incontinence due to neurogenic detrusor overactivity
- Spasticity
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Dysphagia
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Onabotulinumtoxin A CI brief — competitive landscape report
- Onabotulinumtoxin A updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI
Frequently asked questions about Onabotulinumtoxin A
What is Onabotulinumtoxin A?
How does Onabotulinumtoxin A work?
What is Onabotulinumtoxin A used for?
Who makes Onabotulinumtoxin A?
Is Onabotulinumtoxin A also known as anything else?
What drug class is Onabotulinumtoxin A in?
What development phase is Onabotulinumtoxin A in?
What are the side effects of Onabotulinumtoxin A?
What does Onabotulinumtoxin A target?
Related
- Drug class: All Botulinum toxin drugs
- Target: All drugs targeting SNAP-25 (synaptosome-associated protein of 25 kDa)
- Manufacturer: Wake Forest University Health Sciences — full pipeline
- Therapeutic area: All drugs in Neurology, Dermatology, Urology
- Indication: Drugs for Cervical dystonia
- Indication: Drugs for Blepharospasm
- Indication: Drugs for Strabismus
- Also known as: Botox, Botulinum toxin, Dysport, BOTOX, Botox ®, "Allergan"
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing